University of New South Wales
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From University of New South Wales
Brief summaries of recent advances in device research and clinical trials, including an implantable sensor designed to measure cancer progression and treatment, new findings on angiogenesis-suppressing genes that protect Down's syndrome patients from cancer, research that implacates two inflammation-related proteins in breast cancer outcomes, and stem-cell implanted contact lenses that repair corneal damage.
Our monthly update on technology transfer deals--licensing agreements between companies and universities or other research institutions--in the fields of life sciences, including pharmaceuticals, medical devices, in vitro diagnostics and research/analytical instrumentation and reagents.
A roundup of recent medtech strategic alliances, mergers & acquisitions and financings.
The Garvan Institute of Medical Research became an autonomous research institute in 1984. Sponsored research accounts for one-quarter of Garvan's $14 million 1998 operating income. Going forward, it expects its income to derive approximately one-third from grants, one-third from donations, and one third from commercial activities. The bulk of current revenues from commercial activities come from Eli Lilly, Bristol-Myers, and Merck & Co.
- Academic and Research Institutions